Evidence map›Paper›PMID 39961338›Full record

ArticleJournal of the National Cancer Institute2025

Early identification of weight loss trajectories in advanced cancer and associations with survival.

Sophia Fuller, Stacey Alexeeff, Bette Caan, Marcus D Goncalves, Richard F Dunne, Tobias Janowitz, Mariam Jamal-Hanjani, Tilak K Sundaresan, Elizabeth M Cespedes Feliciano

Abstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sophia FullerDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA 94588, United States.ORCID 0000-0001-5682-615X
Stacey AlexeeffDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA 94588, United States.ORCID 0000-0001-8988-6976
Bette CaanDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA 94588, United States.ORCID 0000-0002-5803-310X
Marcus D GoncalvesDepartment of Medicine, NYU Langone Health, New York, NY 10016, United States.ORCID 0000-0002-0784-9248
Richard F DunneWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, United States.ORCID 0000-0001-6608-660X
Tobias JanowitzCold Spring Harbor Laboratory, Cold Spring Harbor, New York, NY 11724, United States.ORCID 0000-0002-7820-3727
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence and Cancer Metastasis Laboratory, University College London Cancer Institute, London WC1E 6BT, United Kingdom.ORCID 0000-0003-1212-1259
Tilak K SundaresanDepartment of Oncology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA 94115, United States.
Elizabeth M Cespedes FelicianoDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA 94588, United States.ORCID 0000-0003-1192-4017

Funding

CANCAN - KaiserOT2CA278691 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI Elizabeth Marjorie Cespedes Feliciano · 2022 to 2026
$2.7M
Cancer Grand ChallengesNational Cancer Institute and Cancer Research OT2CA278691NCI NIH HHS OT2 CA278691
6 · The paper itself

Abstract

Consensus criteria to diagnose unintentional weight loss, a condition often termed cachexia that affects most patients with advanced cancer, are based on 6-month changes by which time intervention is often ineffective. Leveraging the large and diverse population in Kaiser Permanente Northern California's community oncology practice, we studied 8338 patients with advanced lung, pancreatic, or colorectal cancers. We calculated weekly weight change measurements from 2 months pre- to 6 months post-diagnosis to identify 4 weight change trajectories (Gain, Stable, Moderate Loss, and Severe Loss) and associated these trajectories with survival. With high agreement, we classified patients into these trajectories after 3 months and found them to be prognostic; those classified in Moderate (HR = 1.55; 95% CI = 1.45 to 1.67) or Severe Loss (HR = 2.20; 95% CI = 2.01 to 2.41) at 3 months had significantly increased risk of death compared with the Stable trajectory. Weight loss at 3 months post-diagnosis can accurately classify deleterious weight trajectories, allowing for earlier clinical intervention.

Indexed as

CachexiaLung NeoplasmsNeoplasmsWeight LossAdultAgedAged, 80 and overCaliforniaColorectal NeoplasmsFemaleHumansMaleMiddle AgedPancreatic NeoplasmsPrognosis

Identifiers

PMID39961338
PMCPMC13344861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.